HELP is trading 5.02% up at $6.80 following Cybin’s recent financing and pipeline momentum.
- The move is largely attributed to the company's $50 million follow-on offering and continued investor focus on its clinical pipeline and upcoming data.
- Gains are further supported by a broader market rally, with U.S. indices and the biotech sector participating in a firm risk-on tone.